Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
June 13, 2016 01:18 ET
|
SymBio Pharmaceuticals Ltd
TOKYO, June 13, 2016 (GLOBE NEWSWIRE) -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that the Phase 3 clinical trial on “SyB P-1501” – a drug for...
Santen Reports Fiscal 2015 Consolidated Performance
May 11, 2016 03:59 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, May 11, 2016 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended...
Santen Announces Assignment of Its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
May 12, 2015 03:53 ET
|
Santen Pharmaceutical Co., Ltd.
Disclaimer: The following document is a translation of a press release prepared in Japanese. The Japanese version is the original version and can be found on the company's website:...
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
May 12, 2015 03:52 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, May 12, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015)...
Santen Announces Approval of Ikervis for EU Marketing Authorization
March 25, 2015 04:45 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, March 25, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European...
Announcement Regarding the Report by the National Bureau of Investigation in the Philippines
March 18, 2015 06:49 ET
|
Universal Entertainment Corporation
TOKYO, March 18, 2015 (GLOBE NEWSWIRE) -- Universal Entertainment Corporation (hereinafter referred to as the "Company") hereby announces that as reported in the Announcement Regarding Disposition...
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
March 02, 2015 03:23 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, March 2, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA)...
Increase of Capital for a Consolidated Subsidiary in Europe
September 25, 2014 05:31 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen") hereby announces that it was resolved at the Board of Director meeting held on September...
Santen Announces Closing of Asset Purchase Agreement With Respect to Acquisition of Ophthalmology Assets From Merck
July 02, 2014 02:32 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, July 2, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, Japan) (Santen) announced the closing of an asset purchase agreement ("Agreement") which was entered on May 13,...
Universal Entertainment's Response to a Portion of the Media Reports
May 13, 2014 06:33 ET
|
Universal Entertainment Corporation
TOKYO, May 13, 2014 (GLOBE NEWSWIRE) -- The following is an explanation concerning the facts about the truth known to us at this time regarding meetings, etc. in July 2013 between our attorney, Mr....